IN2014MN01577A - - Google Patents
Info
- Publication number
- IN2014MN01577A IN2014MN01577A IN1577MUN2014A IN2014MN01577A IN 2014MN01577 A IN2014MN01577 A IN 2014MN01577A IN 1577MUN2014 A IN1577MUN2014 A IN 1577MUN2014A IN 2014MN01577 A IN2014MN01577 A IN 2014MN01577A
- Authority
- IN
- India
- Prior art keywords
- group
- alkyl group
- alkoxy
- alkyl
- halogenated
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012025754 | 2012-02-09 | ||
| JP2012259122 | 2012-11-27 | ||
| PCT/JP2013/052985 WO2013118854A1 (ja) | 2012-02-09 | 2013-02-08 | シクロアルカン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01577A true IN2014MN01577A (enExample) | 2015-05-08 |
Family
ID=48947609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1577MUN2014 IN2014MN01577A (enExample) | 2012-02-09 | 2013-02-08 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8889741B2 (enExample) |
| EP (2) | EP2813491B1 (enExample) |
| JP (2) | JP5997710B2 (enExample) |
| KR (1) | KR20140127238A (enExample) |
| CN (1) | CN104185629B (enExample) |
| AU (1) | AU2013218592B2 (enExample) |
| BR (1) | BR112014019478A2 (enExample) |
| CA (1) | CA2864222C (enExample) |
| CO (1) | CO7151511A2 (enExample) |
| CY (1) | CY1118572T1 (enExample) |
| DK (1) | DK2813491T3 (enExample) |
| ES (2) | ES2613078T3 (enExample) |
| HR (1) | HRP20161713T1 (enExample) |
| HU (2) | HUE031450T2 (enExample) |
| IL (1) | IL234014A (enExample) |
| IN (1) | IN2014MN01577A (enExample) |
| LT (1) | LT2813491T (enExample) |
| MX (1) | MX349354B (enExample) |
| NZ (1) | NZ628096A (enExample) |
| PH (2) | PH12014501804A1 (enExample) |
| PL (1) | PL2813491T3 (enExample) |
| PT (1) | PT2813491T (enExample) |
| RS (1) | RS55671B1 (enExample) |
| RU (1) | RU2635354C2 (enExample) |
| SG (1) | SG11201404707VA (enExample) |
| SI (1) | SI2813491T1 (enExample) |
| SM (2) | SMT201700053T1 (enExample) |
| TW (1) | TWI612042B (enExample) |
| WO (1) | WO2013118854A1 (enExample) |
| ZA (1) | ZA201405801B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104024251B (zh) * | 2011-10-31 | 2017-08-11 | 克赛农制药股份有限公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| AR091112A1 (es) | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| US9597330B2 (en) | 2013-03-14 | 2017-03-21 | Daiichi Sankyo Company, Limited | Drugs for treating respiratory diseases |
| CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
| MX2015010775A (es) | 2013-03-15 | 2016-04-25 | Genentech Inc | Benzoxazoles sustituidos y metodos para usarlos. |
| EA201691085A1 (ru) | 2013-11-27 | 2017-02-28 | Дженентек, Инк. | Замещенные бензамиды и способы их применения |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP2018520107A (ja) | 2015-05-22 | 2018-07-26 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| CN108349894A (zh) | 2015-11-06 | 2018-07-31 | 第三共株式会社 | 除去二甲氧基苄基的方法 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| TN2018000385A1 (en) * | 2016-05-20 | 2020-06-15 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN110072855A (zh) | 2016-10-17 | 2019-07-30 | 基因泰克公司 | 治疗性化合物及其使用方法 |
| EP3532462B1 (en) * | 2016-10-27 | 2021-10-13 | Bristol-Myers Squibb Company | Acyl sulfonamide nav1.7 inhibitors |
| SG10201912376VA (en) | 2016-12-09 | 2020-02-27 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| EP3684772B1 (en) | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| IL279810B2 (en) | 2018-08-31 | 2025-03-01 | Xenon Pharmaceuticals Inc | Heteroaryl-modified sulfonamide compounds and their use as medicinal agents |
| JP7383012B2 (ja) | 2018-08-31 | 2023-11-17 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用 |
| CN113164461A (zh) * | 2018-12-26 | 2021-07-23 | 拉夸里亚创药株式会社 | 作为Nav1.7及Nav1.8阻断剂的杂环衍生物 |
| US20240241265A1 (en) * | 2023-01-18 | 2024-07-18 | Qualcomm Incorporated | Virtual positioning signal measurements |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6222048B1 (en) | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| ZA200710332B (en) * | 2005-05-16 | 2009-03-25 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| WO2010035166A1 (en) | 2008-09-23 | 2010-04-01 | Pfizer Limited | Benzamide derivatives |
| CU24099B1 (es) * | 2009-01-12 | 2015-06-30 | Pfizer Ltd | Derivados de sulfonamida para el tratamiento del dolor |
| EP2590951B1 (en) * | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| JP5872552B2 (ja) * | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| CN104024251B (zh) * | 2011-10-31 | 2017-08-11 | 克赛农制药股份有限公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
-
2013
- 2013-01-31 US US13/756,173 patent/US8889741B2/en active Active
- 2013-02-07 TW TW102104725A patent/TWI612042B/zh not_active IP Right Cessation
- 2013-02-08 SI SI201330423A patent/SI2813491T1/sl unknown
- 2013-02-08 RS RS20170101A patent/RS55671B1/sr unknown
- 2013-02-08 KR KR1020147021798A patent/KR20140127238A/ko not_active Abandoned
- 2013-02-08 ES ES13746373.3T patent/ES2613078T3/es active Active
- 2013-02-08 RU RU2014136463A patent/RU2635354C2/ru not_active IP Right Cessation
- 2013-02-08 HU HUE13746373A patent/HUE031450T2/en unknown
- 2013-02-08 IN IN1577MUN2014 patent/IN2014MN01577A/en unknown
- 2013-02-08 EP EP13746373.3A patent/EP2813491B1/en active Active
- 2013-02-08 AU AU2013218592A patent/AU2013218592B2/en not_active Ceased
- 2013-02-08 CN CN201380017715.1A patent/CN104185629B/zh not_active Expired - Fee Related
- 2013-02-08 JP JP2013557586A patent/JP5997710B2/ja not_active Expired - Fee Related
- 2013-02-08 PL PL13746373T patent/PL2813491T3/pl unknown
- 2013-02-08 CA CA2864222A patent/CA2864222C/en not_active Expired - Fee Related
- 2013-02-08 WO PCT/JP2013/052985 patent/WO2013118854A1/ja not_active Ceased
- 2013-02-08 HR HRP20161713TT patent/HRP20161713T1/hr unknown
- 2013-02-08 PT PT137463733T patent/PT2813491T/pt unknown
- 2013-02-08 EP EP16193142.3A patent/EP3144300B1/en not_active Not-in-force
- 2013-02-08 NZ NZ628096A patent/NZ628096A/en not_active IP Right Cessation
- 2013-02-08 MX MX2014009637A patent/MX349354B/es active IP Right Grant
- 2013-02-08 HU HUE16193142A patent/HUE037048T2/hu unknown
- 2013-02-08 BR BR112014019478A patent/BR112014019478A2/pt not_active Application Discontinuation
- 2013-02-08 SM SM20170053T patent/SMT201700053T1/it unknown
- 2013-02-08 LT LTEP13746373.3T patent/LT2813491T/lt unknown
- 2013-02-08 ES ES16193142.3T patent/ES2659434T3/es active Active
- 2013-02-08 DK DK13746373.3T patent/DK2813491T3/en active
- 2013-02-08 SG SG11201404707VA patent/SG11201404707VA/en unknown
-
2014
- 2014-08-06 ZA ZA2014/05801A patent/ZA201405801B/en unknown
- 2014-08-07 IL IL234014A patent/IL234014A/en not_active IP Right Cessation
- 2014-08-11 PH PH12014501804A patent/PH12014501804A1/en unknown
- 2014-09-05 CO CO14195847A patent/CO7151511A2/es unknown
- 2014-09-30 US US14/502,708 patent/US9493448B2/en not_active Expired - Fee Related
-
2015
- 2015-11-27 PH PH12015502675A patent/PH12015502675A1/en unknown
-
2016
- 2016-08-26 JP JP2016165515A patent/JP6154052B2/ja not_active Expired - Fee Related
- 2016-09-19 US US15/269,485 patent/US9845313B2/en not_active Expired - Fee Related
-
2017
- 2017-01-24 SM SM201700053T patent/SMT201700053B/it unknown
- 2017-01-31 CY CY20171100142T patent/CY1118572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01577A (enExample) | ||
| IN2014DN03063A (enExample) | ||
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| MX2014015158A (es) | Derivados de piridinona y piridazinona. | |
| IN2014MN01754A (enExample) | ||
| MY198204A (en) | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof | |
| PH12014500842A1 (en) | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| IN2014MN00988A (enExample) | ||
| IN2014MN02652A (enExample) | ||
| IN2015DN01119A (enExample) | ||
| NZ607580A (en) | N-heteroaryl compounds | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| MY169485A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| WO2013106761A3 (en) | Antimicrobial agents | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| PH12012501552A1 (en) | Therapeutic or prophylactic agent for biliary diseases | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| IN2014DN11023A (enExample) | ||
| NZ700507A (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| WO2014060942A3 (en) | Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases |